Annual SG&A
$60.70 M
+$20.89 M+52.47%
31 December 2023
Summary:
Vaxcyte annual selling, general & administrative expenses is currently $60.70 million, with the most recent change of +$20.89 million (+52.47%) on 31 December 2023. During the last 3 years, it has risen by +$44.68 million (+278.97%). PCVX annual SG&A is now at all-time high.PCVX Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$22.99 M
+$1.51 M+7.05%
30 September 2024
Summary:
Vaxcyte quarterly selling, general & administrative expenses is currently $22.99 million, with the most recent change of +$1.51 million (+7.05%) on 30 September 2024. Over the past year, it has increased by +$7.38 million (+47.31%). PCVX quarterly SG&A is now at all-time high.PCVX Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$4.34 B
-$507.65 M-13.24%
30 September 2024
Summary:
Vaxcyte TTM selling, general & administrative expenses is currently -$4.34 billion, with the most recent change of -$507.65 million (-13.24%) on 30 September 2024. Over the past year, it has dropped by -$4.40 billion (-7978.74%). PCVX TTM SG&A is now -3871.90% below its all-time high of $81.87 million, reached on 30 September 2024.PCVX TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PCVX Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +52.5% | +47.3% | -7978.7% |
| 3 y3 years | +279.0% | +252.4% | -10000.0% |
| 5 y5 years | +1026.6% | +815.9% | -10000.0% |
PCVX Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +279.0% | at high | +252.4% | -366.1% | at low |
| 5 y | 5 years | at high | +1026.6% | at high | +835.6% | -3871.9% | at low |
| alltime | all time | at high | +1026.6% | at high | +1646.8% | -3871.9% | at low |
Vaxcyte Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $22.99 M(+7.1%) | $81.87 M(+9.9%) |
| June 2024 | - | $21.47 M(+8.0%) | $74.49 M(+10.4%) |
| Mar 2024 | - | $19.89 M(+13.5%) | $67.47 M(+11.2%) |
| Dec 2023 | $60.70 M(+52.5%) | $17.53 M(+12.3%) | $60.70 M(+10.1%) |
| Sept 2023 | - | $15.61 M(+7.9%) | $55.13 M(+9.3%) |
| June 2023 | - | $14.46 M(+10.3%) | $50.42 M(+11.1%) |
| Mar 2023 | - | $13.11 M(+9.7%) | $45.38 M(+14.0%) |
| Dec 2022 | $39.81 M(+57.6%) | $11.95 M(+9.7%) | $39.81 M(+15.0%) |
| Sept 2022 | - | $10.90 M(+15.7%) | $34.63 M(+14.5%) |
| June 2022 | - | $9.42 M(+24.8%) | $30.25 M(+12.4%) |
| Mar 2022 | - | $7.54 M(+11.4%) | $26.92 M(+6.6%) |
| Dec 2021 | $25.26 M | $6.77 M(+3.8%) | $25.26 M(+8.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2021 | - | $6.52 M(+7.3%) | $23.28 M(+7.5%) |
| June 2021 | - | $6.08 M(+3.3%) | $21.65 M(+16.3%) |
| Mar 2021 | - | $5.88 M(+22.8%) | $18.62 M(+16.3%) |
| Dec 2020 | $16.02 M(+87.4%) | $4.79 M(-2.2%) | $16.02 M(+17.1%) |
| Sept 2020 | - | $4.90 M(+60.8%) | $13.68 M(+21.1%) |
| June 2020 | - | $3.05 M(-7.2%) | $11.29 M(+7.4%) |
| Mar 2020 | - | $3.28 M(+33.5%) | $10.51 M(+23.0%) |
| Dec 2019 | $8.55 M(+58.6%) | $2.46 M(-2.1%) | $8.55 M(+40.3%) |
| Sept 2019 | - | $2.51 M(+10.9%) | $6.09 M(+70.1%) |
| June 2019 | - | $2.26 M(+72.0%) | $3.58 M(+172.0%) |
| Mar 2019 | - | $1.32 M | $1.32 M |
| Dec 2018 | $5.39 M | - | - |
FAQ
- What is Vaxcyte annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Vaxcyte?
- What is Vaxcyte annual SG&A year-on-year change?
- What is Vaxcyte quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Vaxcyte?
- What is Vaxcyte quarterly SG&A year-on-year change?
- What is Vaxcyte TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Vaxcyte?
- What is Vaxcyte TTM SG&A year-on-year change?
What is Vaxcyte annual selling, general & administrative expenses?
The current annual SG&A of PCVX is $60.70 M
What is the all time high annual SG&A for Vaxcyte?
Vaxcyte all-time high annual selling, general & administrative expenses is $60.70 M
What is Vaxcyte annual SG&A year-on-year change?
Over the past year, PCVX annual selling, general & administrative expenses has changed by +$20.89 M (+52.47%)
What is Vaxcyte quarterly selling, general & administrative expenses?
The current quarterly SG&A of PCVX is $22.99 M
What is the all time high quarterly SG&A for Vaxcyte?
Vaxcyte all-time high quarterly selling, general & administrative expenses is $22.99 M
What is Vaxcyte quarterly SG&A year-on-year change?
Over the past year, PCVX quarterly selling, general & administrative expenses has changed by +$7.38 M (+47.31%)
What is Vaxcyte TTM selling, general & administrative expenses?
The current TTM SG&A of PCVX is -$4.34 B
What is the all time high TTM SG&A for Vaxcyte?
Vaxcyte all-time high TTM selling, general & administrative expenses is $81.87 M
What is Vaxcyte TTM SG&A year-on-year change?
Over the past year, PCVX TTM selling, general & administrative expenses has changed by -$4.40 B (-7978.74%)